Drugs That Target Neurological Diseases Are Tricky, Risky And Expensive. But Two Start-Ups Think They Have A Short-Cut.

The companies are taking compounds that already exist, tailoring receptors to match them, and delivering the genetic code for those bespoke receptors as a gene therapy. In other pharmaceutical news: a heartburn drug recall, drug shortages, and a biotech scorecard from Stat.

from Kaiser Health News https://ift.tt/2JxQVM7